Bio-Path Holdings filings document a clinical-stage biotechnology issuer focused on DNAbilize® liposomal delivery and antisense RNAi nanoparticle drug candidates. Material-event reports, exchange notices and late-filing notifications address governance, operating continuity, financing and capital-structure disclosures, and the common stock's registration or trading status.
The company's recent filings also record corporate-status and governance matters, including Nasdaq removal from listing, OTC Pink common stock disclosure, Wyoming domestication, creation of Series S Preferred stock, board and executive changes, a late Form 10-Q notification, and an operational pause instituted to conserve capital.
Bio-Path Holdings, Inc. reported several corporate updates. The company’s domestication to Wyoming was approved by the Wyoming Secretary of State on March 5, 2026, and it filed an amendment creating a new Series S Preferred Stock class with 51 authorized shares, each convertible into one common share and carrying 1% of the company’s diluted voting power.
Effective February 10, 2026, Bio-Path appointed Wendy M. Charles, PhD and Michael Hickey to its newly formed Scientific Advisory Board. Both entered three-year advisory agreements and each received 100,000 stock options with a $0.06 exercise price and a three-year expiration, subject to adjustment.
Bio-Path Holdings, Inc. reported several governance and strategic actions, including issuing Steel Giants Advisors LLC 51 shares of new Series S Preferred stock and 2,000,000 common stock purchase warrants in exchange for $10,000 of accrued payables. The company filed to domesticate from Delaware to Wyoming, expecting approval in March 2026, and is negotiating with creditors while evaluating restarting certain Phase 1 and Phase 2 drug trials. Bio-Path engaged Farrington Capital Group for technology and strategic support, paying $1,000 and issuing 100,000 restricted common shares, created a Strategic Advisory Board with associated option incentives, and, together with its majority holder, canceled a previously approved 1-for-30 reverse stock split, concluding it was not in shareholders’ interests.
Bio-Path Holdings, Inc. reports a third-quarter 2025 net loss of $1.0 million, narrower than the prior-year quarter, as operating expenses fell sharply after the company paused most activities. For the nine months ended September 30, 2025, the net loss was $8.4 million.
Cash fell to $0.0 million at September 30, 2025, with total assets of $0.7 million against current liabilities of $8.7 million, resulting in shareholders’ deficit equity of $(8.0) million. Management states that available cash will not fund the next 12 months, and explicitly concludes that substantial doubt exists about the company’s ability to continue as a going concern.
The company has furloughed most employees and instituted a company‑wide operational pause to conserve capital, while relying on dilutive financings and high‑cost promissory notes that carry default penalties and conversion features. Notes issued in March 2025 are already in default and an April 2025 note defaulted after quarter end, creating a derivative liability of $0.3 million. Subsequent events include appointment of a new CEO/CFO, engagement of a restructuring advisor granted inexpensive warrants and majority voting power via new Series S preferred shares, and additional small promissory notes in January 2026.
Bio-Path Holdings, Inc. filed a Form 12b-25 to notify the SEC and investors that its Form 10-Q for the quarter ended September 30, 2025 will be filed late. The company states it is still compiling the necessary information for the quarterly report and that all information has not yet been received due to a change in management. Bio-Path indicates it expects to file the Form 10-Q within the permitted grace period after the original due date.
Bio-Path Holdings (BPTH) filed an 8-K announcing a board change and financing plans. The Board accepted the resignation of Director Douglas Morris, delivered electronically on November 4, 2025 and accepted on November 13, 2025.
The company is seeking financing to support a planned turnaround that it anticipates will include updating its finance team, engaging new PCAOB auditors, hiring investment bankers to review its biotech portfolio for sale or partnerships, and pursuing strategic mergers and acquisitions. The company cautions that there can be no assurances of success. If capital cannot be raised, the company states there is substantial doubt about its ability to continue as a going concern and to remain listed on the OTC Markets or other public trading platforms.
Bio-Path Holdings (BPTH) announced leadership changes. On October 22, 2025, the Board appointed Vikram Grover as President, Chief Executive Officer, Chief Financial Officer, and a member of the Board. The Board also accepted the resignation of Douglas Morris as Interim CEO and Interim CFO; he remains on the Board. In addition, Paul Aubert resigned as a Director.
This consolidates executive leadership under one individual while maintaining board continuity through Mr. Morris’s continued service. The filing does not include financial results or strategic updates, focusing solely on governance and leadership transitions.